Physician profile
Sujan Pathak
NPI 1689864449
$4,398.26
in general payments reported to CMS, 2019-2025
33 companies · $680 in 2025
The $680 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $447 · 2020: $239 · 2021: $530 · 2022: $743 · 2023: $751 · 2024: $1,009 · 2025: $680.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,394 · Education: $45.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,394.24 |
| Education | $45.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $592.92 | 2019-2025 | Velphoro, Velphoro, Korsuva |
| Novartis Pharmaceuticals Corporation | $521.17 | 2023-2025 | |
| Amgen INC. | $466.08 | 2019-2025 | Krystexxa, Tavneos, Parsabiv |
| Astrazeneca Pharmaceuticals Lp | $355.24 | 2019-2025 | Farxiga, Lokelma |
| Novo Nordisk INC | $307.26 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Vifor Pharma, INC. | $251.72 | 2019-2023 | Korsuva, Veltassa |
| Opko Pharmaceuticals, LLC | $194.50 | 2019-2024 | Rayaldee |
| Calliditas Therapeutics US INC. | $174.32 | 2022-2025 | Tarpeyo |
| Aurinia Pharma U.S., INC. | $162.28 | 2021-2025 | Lupkynis |
| Glaxosmithkline, LLC. | $137.63 | 2021-2025 | Shingrix, Arexvy, Benlysta |
| Otsuka America Pharmaceutical, INC. | $133.68 | 2019-2025 | Voyxact, Jynarque |
| Pharmacosmos Therapeutics INC. | $117.13 | 2022-2025 | Monoferric |
| Ardelyx, INC. | $106.92 | 2023-2025 | Ibsrela |
| Travere Therapeutics, INC. | $96.95 | 2021-2025 | Filspari |
| Daiichi Sankyo INC. | $90.40 | 2019-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.38 | 2023-2025 | Jardiance |
| Horizon Therapeutics Plc | $85.39 | 2023 | Krystexxa |
| Alexion Pharmaceuticals, INC. | $84.43 | 2019-2025 | Ultomiris |
| Bayer Healthcare Pharmaceuticals INC. | $73.63 | 2022-2023 | |
| Mallinckrodt Hospital Products INC. | $62.49 | 2021-2024 | Terlivaz |
| Veloxis Pharmaceuticals, INC. | $37.83 | 2022-2025 | Envarsus |
| La Jolla Pharmaceutical Company | $36.78 | 2019-2020 | |
| Shield Therapeutics INC | $36.09 | 2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $33.33 | 2023-2025 | Jynarque |
| Ani Pharmaceuticals, INC. | $23.99 | 2022 | |
| Lilly USA, LLC | $22.19 | 2023 | Jardiance |
| Ultragenyx Pharmaceutical INC. | $18.27 | 2022 | |
| Alnylam Pharmaceuticals INC. | $18.00 | 2023 | Onpattro |
| Takeda Pharmaceuticals U.S.A., INC. | $15.60 | 2020 | |
| Akebia Therapeutics INC | $14.86 | 2019 | |
| Scpharmaceuticals INC. | $14.34 | 2025 | |
| Mallinckrodt Enterprises LLC | $12.87 | 2019 | |
| Amag Pharmaceuticals, INC. | $11.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sujan Pathak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.